The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | Finding the right targets for CAR T-cell therapy in AML
CAR T-cell therapy is becoming increasingly prominent in various hematological malignancies; however, its application in acute myeloid leukemia (AML) has faced some challenges, as Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, explains at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX. She discusses the struggle of finding the right antigen target in AML, since targeting a generic antigen would result in devastating myelosuppression. Targets currently being researched include CD33, CD123 and CLL1, and Prof. Konopleva evaluates the potential of each in this video.
